Updated:
CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. is a publicly traded entity, distinct from a traditional family office or asset manager. The firm's core mandate involves the...
CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. is a publicly traded entity, distinct from a traditional family office or asset manager. The firm's core mandate involves the development of novel pharmaceuticals derived from cannabinoid compounds. Public records indicate a focus on oncology indications, including a lead program targeting glioblastoma. The company operates within the biotechnology sector, deploying capital into research and development, clinical trials, and intellectual property portfolio building. CNBX Pharmaceuticals has a known presence in the United States and Israel, leveraging research and development operations in both regions. The firm's pipeline is centered on proprietary formulations, though specific asset-class breakdowns and fund structures typical of investment firms do not apply. Scaled as a development-stage public company, CNBX Pharmaceuticals has disclosed financials through regulatory filings. Team size and specific professionals are not publicly detailed in readily accessible primary sources. The firm does not operate parallel philanthropic or investment vehicles that are publicly reported. As a public pharmaceutical company, CNBX Pharmaceuticals is structurally differentiated by its corporate form, with transparency obligations through SEC filings and a mandate defined by clinical milestones rather than investment returns. Its approach to drug development is governed by regulatory pathway requirements, not discretionary capital allocation.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is CNBX Pharmaceuticals Inc.'s primary business focus?
CNBX Pharmaceuticals Inc. is a publicly traded biopharmaceutical company focused on developing proprietary cannabinoid-based drug formulations. Its primary clinical programs target oncology, including a lead asset for glioblastoma multiforme (per public regulatory filings).
Is CNBX Pharmaceuticals Inc. a family office or investment firm?
No. CNBX Pharmaceuticals Inc. is a public biotechnology company listed on a stock exchange. It is not structured as a family office or asset manager. Its capital is deployed into drug research and development, not external financial investments.
Which therapeutic areas does CNBX Pharmaceuticals target?
The firm's pipeline is concentrated in oncology, with specific focus on glioblastoma (a form of brain cancer). It also explores cannabinoid-based treatments for other central nervous system conditions, as indicated in its public disclosures.
Where does CNBX Pharmaceuticals conduct its operations?
The company maintains operations in the United States and Israel, leveraging research and clinical development capabilities in both countries. Its specific headquarters address is not publicly highlighted in easily accessible primary sources.
How does CNBX Pharmaceuticals fund its research?
As a publicly traded company, CNBX Pharmaceuticals raises capital through equity markets and public offerings. It does not function as an allocator of external family capital. Financial details are disclosed in periodic SEC filings (per public record).
What is the regulatory status of CNBX Pharmaceuticals' lead drug candidate?
The company's lead candidate is in Phase 2 clinical trials for the treatment of glioblastoma. The firm has reported interim positive results, though it remains in the development stage with no approved products marketed (per company press releases).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: